Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve) (Retrieve)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00605332
Recruitment Status : Completed
First Posted : January 31, 2008
Last Update Posted : August 6, 2012
Information provided by (Responsible Party):
Crux Biomedical

Brief Summary:
This is an open label, non-randomized, prospective, multicenter study.

Condition or disease Intervention/treatment Phase
Pulmonary Embolism Device: inferior vena cava filter Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System - ("Retrieve")
Study Start Date : October 2007
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
Device: inferior vena cava filter
Crux Biomedical IVC Filter
Other Name: No other names

Primary Outcome Measures :
  1. Primary Efficacy Objective: To describe the clinical utility of the Crux IVCF by the following criteria: Absence of a recurrent PE and IVC thrombosis related to the Crux IVCF. [ Time Frame: 30 days post implant, 30 days post retrieval. Patients with indwelling filters will return 1 and 6 months post implant procedure. ]

Secondary Outcome Measures :
  1. Primary Safety Objective: To estimate the proportion of patients who experience device/procedure related complications associated with the Crux IVCF. [ Time Frame: 30 days post implant procedure and 30 days post retrieval procedure. Patients with indwelling filters will return 1 and 6 months post implant procedure. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients for this study must meet the following inclusion criteria to be eligible for enrollment:

  1. The patient is >18 years of age.
  2. Patient is considered a candidate for the IVCF under one of the following indications:

    • Proven PE
    • Recurrent PE despite adequate anticoagulation
    • Contraindication to anticoagulation
    • Inability to achieve/maintain therapeutic anticoagulation
    • Iliocaval DVT
    • Large, free-floating proximal (i.e. ileofemoral) DVT
    • Massive PE treated with thrombolysis/thrombectomy
    • Chronic PE treated with thrombectomy
    • Protection during thrombolysis for iliocaval DVT
    • PE with limited cardiopulmonary reserve
    • Poor compliance with anticoagulant medications
    • High risk of injury worsened by anticoagulation (e.g., ataxia, falls)
    • Multi-trauma patient with high risk of PE
    • Surgical patients at high risk of PE
    • Medical condition with high risk of PE
  3. Patient has a vena cava diameter of 17-28mm.
  4. The patient or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent.
  5. The patient is willing to be available for the appropriate follow-up for the duration of the study.
  6. The patient has suitable IVC anatomy that would allow infra-renal placement of the filter.

Exclusion Criteria:

Patients who have ANY of the following exclusion criteria are NOT eligible for the study:

  1. The patient has one of the following conditions:

    • Renal vein thrombosis
    • IVC thrombosis extending to renal veins
    • Duplicate IVC
    • Gonadal vein thrombosis
    • Requires supra-renal filter placement
  2. The patient has an uncontrolled infectious disease.
  3. The patient is at risk for aseptic PE.
  4. Patient has uncontrollable coagulopathy.
  5. Patient has an existing IVCF.
  6. The patient has a life expectancy of less than 6 months.
  7. The patient is pregnant.
  8. The patient has a condition that inhibits radiographic visualization of the IVC.
  9. The patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol.
  10. The patient has a known hypersensitivity to contrast which cannot be pre-treated.
  11. The patient's access vessels preclude safe insertion of the delivery system.
  12. The patient is participating in another device or drug study. Patient must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this trial. The patient may only be enrolled in this study once.
  13. The patient is unable and/or unwilling to cooperate with study procedures or required follow-up visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00605332

Sponsors and Collaborators
Crux Biomedical
Principal Investigator: David Rosenthal, MD Atlanta Vascular Specialists
Study Director: Mel Schatz Crux Biomedical

Responsible Party: Crux Biomedical Identifier: NCT00605332     History of Changes
Other Study ID Numbers: RETRIEVE I
First Posted: January 31, 2008    Key Record Dates
Last Update Posted: August 6, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Pulmonary Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases